A Phase 2 Randomized, Double-blind, Placebo-controlled Trial of Ambroxol as a Disease-modifying Treatment for Parkinson's Disease Dementia

被引：0
|
作者：
Pasternak, S.
Silveira, C.
Coleman, K.
Garcia, R.
Wells, J.
Borrie, M.
MacDonald, P.
Bartha, R.
Jenkins, M.
Morrow, S.
Mendonca, D.
Zou, G.
Finger, E.
Rupar, T.
Tirona, R.
Jog, M.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
106
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [21] Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
    Vivash, Lucy
    Bertram, Kelly L.
    Malpas, Charles B.
    Marotta, Cassandra
    Harding, Ian H.
    Kolbe, Scott
    Fielding, Joanne
    Clough, Meaghan
    Lewis, Simon J. G.
    Tisch, Stephen
    Evans, Andrew H.
    O'Sullivan, John D.
    Kimber, Thomas
    Darby, David
    Churilov, Leonid
    Law, Meng
    Hovens, Christopher M.
    Velakoulis, Dennis
    O'Brien, Terence J.
    BMJ OPEN, 2021, 11 (12):
  • [22] Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
    Butchart, Joseph
    Brook, Laura
    Hopkins, Vivienne
    Teeling, Jessica
    Puentener, Ursula
    Culliford, David
    Sharples, Richard
    Sharif, Saif
    McFarlane, Brady
    Raybould, Rachel
    Thomas, Rhodri
    Passmore, Peter
    Perry, V. Hugh
    Holmes, Clive
    NEUROLOGY, 2015, 84 (21) : 2161 - 2168
  • [23] ETANERCEPT IN ALZHEIMER DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 2 TRIAL
    Tufan, Ayse N.
    Tufan, Fatih
    NEUROLOGY, 2015, 85 (23) : 2083 - 2084
  • [24] Donepezil for dementia in Parkinson's disease: A randomized, double-blind, placebo-controlled, crossover study.
    Ravina, B
    Putt, M
    Siderowf, A
    Farrar, JT
    Gillespie, M
    Crawley, A
    Fernandez, H
    Treischmann, M
    Reichwein, S
    Simuni, T
    MOVEMENT DISORDERS, 2004, 19 (09) : 1132 - 1133
  • [25] A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
    Vivash, Lucy
    Malpas, Charles B.
    Churilov, Leonid
    Walterfang, Mark
    Brodtmann, Amy
    Piguet, Olivier
    Ahmed, Rebekah M.
    Bush, Ashley, I
    Hovens, Christopher M.
    Kalincik, T.
    Darby, David
    Velakoulis, Dennis
    O'Brien, Terence J.
    BMJ OPEN, 2020, 10 (11):
  • [26] Atomoxetine for the Treatment of Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
    Weintraub, Daniel
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 17 (03): : A67 - A67
  • [27] Atomoxetine for the treatment of depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study
    Weintraub, D.
    Mavandadi, S.
    Horn, S.
    Hurtig, H.
    Siderowf, A.
    Duda, J.
    Stern, M.
    MOVEMENT DISORDERS, 2009, 24 : S286 - S286
  • [28] A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
    Mizuno, Yoshikuni
    Hattori, Nobutaka
    Kondo, Tomoyoshi
    Nomoto, Masahiro
    Origasa, Hideki
    Takahashi, Ryosuke
    Yamamoto, Mitsutoshi
    Yanagisawa, Nobuo
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (05) : 201 - 207
  • [29] GRoningen Early-Parkinson's disease (PD) Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation
    Siemeling, O.
    Slingerland, S.
    Van der Zee, S.
    van Laar, T.
    MOVEMENT DISORDERS, 2024, 39 : S321 - S322
  • [30] Liraglutide once daily versus placebo in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Wu, T.
    Bresee, C.
    Wertheimer, J.
    Hogg, E.
    Malatt, C.
    Tan, E.
    Pomeroy, H.
    Obialisi, G.
    Tagliati, M.
    MOVEMENT DISORDERS, 2022, 37 : S359 - S360
12345